HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Minimally invasive direct coronary artery bypass in a patient with idiopathic thrombocytopenic purpura; report of a reoperative case].

Abstract
A 77-year-old man who had undergone coronary artery bypass grafting (CABG) to segment 3, 7 and 12-14 with saphenous vein grafts (SVG) 15 years before, and ligation of coronary arteriovenous (AV) fistula 8 years before was admitted to our hospital, and diagnosed as acute heart failure and idiopathic thrombocytopenic purpura. Coronary angiography showed multiple stenosis of three vessels, and the grafts to segment 3 and 7 were occluded. The area of left anterior descending (LAD) had no viability, but the inferior wall had viability on dobutamine load echocardiography. The platelet count was about 5.0 x 10(4)/mm3. Minimally invasive direct coronary artery bypass (MIDCAB) for right coronary artery (RCA) using right internal thoracic artery (RITA) was performed through right parasternotomy. Operative and postoperative bleeding was slight, and postoperative course was uneventful. Reoperative MIDCAB can be safely performed in a patient with idiopathic thrombocytopenic purpura, and should be considered a viable alternative for highrisk patients.
AuthorsH Gotoh, Y Fukaya, T Kohno, J Amano
JournalKyobu geka. The Japanese journal of thoracic surgery (Kyobu Geka) Vol. 55 Issue 12 Pg. 1049-52 (Nov 2002) ISSN: 0021-5252 [Print] Japan
PMID12428340 (Publication Type: Case Reports, English Abstract, Journal Article)
Topics
  • Aged
  • Coronary Artery Bypass (methods)
  • Coronary Disease (surgery)
  • Graft Occlusion, Vascular (surgery)
  • Humans
  • Male
  • Minimally Invasive Surgical Procedures
  • Purpura, Thrombocytopenic, Idiopathic (complications)
  • Reoperation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: